Bioaerosol Science

Bioaerosol Efficacy Testing Room

Measure how room or duct devices reduce airborne microbes using controlled chambers and defined organism panels.

We run chamber or duct studies with viable samplers and culture, qPCR, or ddPCR endpoints to report log reduction versus time.

ISO 17025ASHRAE 241AHAM AC-1ASTM E3273Reviewed 2026-10-20
Request a quoteSubmit a sample

Purpose & when to use

Room bioaerosol efficacy testing measures how room-scale or in-duct devices reduce airborne microbial concentrations over time. We use controlled chambers or duct sections, nebulized organism surrogates, viable impingers, and filter collection with culture, qPCR, or droplet digital PCR (ddPCR) endpoints. The data support ISO 17025 records and can support ASHRAE 241 or AHAM AC-1 aligned performance claims under the tested conditions:

  1. Room air cleaner benchmarking under ASHRAE 241 context, using chamber release, viable sampling, and log reduction curves for portable or fixed air-treatment devices.
  2. UVGI design verification for room or duct systems, using ISO 17025 records, UV dose logging, airflow data, and viable recovery to compare operating modes.
  3. In-duct HVAC evaluation uses a configuration-specific protocol defining flow, sampling, recovery, and device-off controls. Adaptations from ASTM E3273 or ISO 16000-36 chamber controls are identified separately from the in-duct method.
  4. EPA OPP claim support for antimicrobial or air-treatment products, using organism selection, recovery validation, and replicate chamber runs matched to the claim language.
  5. AHAM AC-1 adjacent air cleaner studies under ISO 17025 records, using controlled bioaerosol challenges and device-off decay baselines to translate particle CADR concepts into microbial reduction data.

Use room bioaerosol efficacy testing when the decision depends on measured microbial reduction under defined airflow, mixing, relative humidity (RH), and temperature conditions. Before testing begins, the study plan sets the organism panel, chamber or duct configuration, endpoints, and aligned standards.

Built for room and duct air-treatment devices

Bioaerosol efficacy studies serve air-treatment products where microbial reduction, airflow, and operating mode all affect the claim. Device setup is mapped to ASHRAE, AHAM, ASTM, EPA, or ISO expectations during planning.

  • Air cleanersPortable and room-scale units
  • UVGI unitsRoom and in-duct systems
  • HVAC add-onsDuct-mounted treatment devices
  • Hybrid devicesFiltration plus active treatment
  • Control systemsMode and airflow logic

Instrumentation & measurement ranges

We select the platform based on device geometry, organism panel, endpoint sensitivity, and airflow conditions.

1 – 30 m³chamber-volume

Room chambers and duct sections

Controlled enclosures or duct runs define device placement, release location, mixing strategy, airflow, and sampling positions for room-scale or in-duct efficacy studies.

0.1 – 10 mL/minliquid-feed

Bioaerosol nebulizers and generators

Generate organism or surrogate challenges at defined release conditions, with background checks and recovery controls matched to the selected endpoint.

1 – 30 L/minsampler-flow

Viable samplers and filter trains

Impingers, filter holders, and timed collection trains capture airborne organisms at baseline and post-treatment intervals for concentration decay analysis.

10 – 10000000 copiesquantitation

Culture, qPCR, and ddPCR endpoints

Culture and molecular endpoints convert collected samples into viable counts, gene copies, or absolute copy number depending on organism and claim frame.

20 – 80 RHcondition-control

Environmental and UV measurement

Temperature, relative humidity, airflow, device mode, and UV irradiance or dose are logged where they affect recovery, inactivation, or comparison across runs.

Test method options

MethodStrengthsTradeoffAligned with
Room infectious aerosol reduction study
  • ASHRAE 241 aligned chamber data links microbial reduction to room-scale air-treatment decisions and equivalent clean airflow concepts.
  • Device-off controls and timed viable sampling distinguish natural decay from device-driven reduction across operating modes.
Mixing, room volume, organism recovery, and baseline decay must be controlled tightly before log reduction values can be compared.
ASHRAE 241ISO 17025
Portable air cleaner microbial efficacy study
  • AHAM AC-1 aligned chamber structure supports portable air-cleaner comparisons using defined release, mixing, and decay intervals.
  • Culture, qPCR, or ddPCR endpoints allow organism-specific reporting where particle-only CADR data are not enough.
AHAM AC-1 is not a complete microbial-kill protocol, so organism recovery and endpoint validation need added study controls.
AHAM AC-1ISO 17025
Duct or claim-support efficacy study
  • ASTM E3273, EPA OPP, and ISO 16000-36 alignment can support air-treatment or antimicrobial claim files when the device and organism fit.
  • Duct fixtures, UV dose logging, and airflow records help compare in-duct units, UVGI systems, and hybrid devices under installed-use conditions.
Regulatory fit depends on claim language, organism selection, biosafety limits, and whether the device is room-scale, in-duct, or surface-adjacent.
ASTM E3273EPA OPPISO 16000-36

Setup configurations

Every room efficacy study starts by defining device placement, challenge organism, release strategy, airflow, and endpoint. These choices help distinguish decay attributable to the device from background loss, sampler behavior, or environmental drift. The study protocol fixes the following chamber or duct setup dimensions before testing begins:

Device interfaces

Room placement, duct insertion, UVGI mounting, or fixture adaptation documented with device mode, flow path, and distance from release and sampling points.

Exposure profile

Defined organism release, mixing time, device-on interval, sampling schedule, and run duration matched to the expected reduction rate.

Environmental controls

Temperature, RH, airflow, background aerosol, and UV dose or irradiance logged where they affect survival, transport, or inactivation.

Sample numbers

Replicate device-on runs, device-off controls, blanks, and background checks sized to the study decision and expected variability.

Calibration & verification

Sampler flow, nebulizer output, assay controls, environmental sensors, and UV meters verified before or during each campaign.

Methods anchored to the standards that matter

Room efficacy studies distinguish the laboratory's accredited quality system from the performance frameworks used for the study. The four standards below define study records, chamber controls, and reporting language.

  • ISO 17025AccreditedTesting-laboratory competence, calibration traceability, method records, and data review.
  • ASHRAE 241AlignedInfectious aerosol risk management and equivalent clean airflow context.
  • AHAM AC-1AlignedPortable air cleaner chamber-performance context for room device studies.
  • ASTM E3273AlignedAirborne microorganism reduction context for chamber efficacy claims.

Key data outputs & reporting

Bioaerosol efficacy reports show how airborne microbial concentration changes over time as the device operates. We report baseline decay, device-on decay, log reduction, replicate statistics, assay recovery, and environmental conditions, along with UV or airflow records where used. QA / QC evidence helps explain which claims the data can support in technical files, during claim review, or when making design decisions.

Primary outputs

  • Airborne microbial concentration versus time for device-on and device-off runs, with sampling interval, endpoint, and recovery basis stated.
  • Log reduction versus time and condition, including operating mode, airflow, UV dose where applicable, and replicate statistics.
  • Assay and sampler performance summaries covering blanks, recovery checks, standard curves, extraction controls, and quantitation limits.
  • Environmental and configuration records tied to each run, including RH, temperature, chamber or duct geometry, release position, and device settings.

Deliverables

#FormatContents
01PDF reportMethods, conditions, controls, reduction results, QA / QC, and study interpretation.
02CSV / XLSX datasetsRun-level concentrations, log reductions, recovery checks, and environmental records.
03FiguresDecay curves, log reduction plots, condition overlays, and mode comparisons.

QA / QC & data integrity

Room bioaerosol studies use controls to distinguish device efficacy from chamber loss, assay variability, and sampling artifacts. We maintain records under the ISO 17025 quality system from organism receipt or preparation through final data review. Those records provide traceability for instruments, samples, analytical endpoints, and reported calculations.

Device-off controls and background runs define natural decay and pre-challenge chamber conditions.

Sampler blanks, media blanks, and extraction controls track contamination and assay background.

Recovery checks for impingers, filters, extraction steps, and culture or molecular assays support quantitation limits.

Replicate runs and repeated sequences quantify variability across device modes, organisms, or airflow settings.

Calibration records cover sampler flow, airflow, RH, temperature, and UV radiometers when UVGI is tested.

Chain of custody tracks organisms, collected samples, extracts, devices, and raw instrument files.

RESEARCH / THIS WORK IN PRACTICE

Real studies. Measured evidence.

Explore published studies connected to bioaerosol efficacy testing. Each explains the study question, approach and findings.

View related studies (3)
Air-Cleaner Performance

Glow Guardian Development and Bioaerosol Testing at ARE Labs

The work helped the client move from concept to a public-facing product story supported by controlled bioaerosol data and a granted patent.

Selected finding
The final broad-range study showed measurable reductions across virus surrogates, bacteria, mold spores, and bacterial endospores.
BioaerosolAir cleanerFormulation development
Air-Cleaner Performance

First-Minute Bioaerosol Testing for Active-in-Air Devices

The method addressed a product-mechanism question that standard chamber decay testing does not isolate: what viable bioaerosol concentration remains one minute after a new challenge enters room air that has already been treated?

Selected finding
The method compared viable bioaerosol concentration after a one-minute post-aerosolization mixing period in matched control and pretreated-room conditions.
BioaerosolAir cleanerDevice evaluation
Air-Cleaner Performance

School Air Purifier Field Study: Bacteria and Attendance

The work compared repeated bacterial air samples and attendance observations under occupied-school conditions.

Selected finding
Illness-related absenteeism was also lower during the same seven-week period; the observational study does not establish causation.
Related context

The occupied-school field study complements controlled room-scale bioaerosol testing without being presented as the same design.

BioaerosolAir cleanerField study

Study-specific findings do not guarantee performance for another product.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
17025Accredited testing
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

These answers cover questions air-treatment developers, UVGI teams, HVAC engineers, and antimicrobial product teams ask when planning room bioaerosol efficacy studies. Topics include organism choice, chamber versus duct setup, log reduction calculations, controls, UV dose records, molecular endpoints, and deliverables. Contact us if your device geometry, claim language, or biosafety requirements fall outside the examples below.

Q.Which organisms can you use?
A.We select organisms or surrogates that match the claim, biosafety requirements, and endpoint sensitivity. The plan includes recovery checks so the sampler and assay can support the intended log reduction calculation.
Q.How is log reduction calculated?
A.We calculate log reduction from measured airborne concentration over time by comparing device-on runs with device-off decay controls. We report sampling volume, recovery, endpoint sensitivity, and replicate statistics with the result.
Q.Can you test a duct device instead of a room device?
A.Yes. Duct studies suit in-duct UVGI, filtration, or active treatment devices when the installed condition is a controlled flow path rather than an open room.
Q.Do you support UVGI efficacy studies?
A.Yes. UVGI studies can include UV irradiance or dose logging, airflow records, device mode settings, and viable recovery endpoints. These records help interpret the measured reduction against the exposure conditions.
Q.What do I receive after testing?
A.You receive a PDF report, CSV or XLSX datasets, and figures showing concentration decay, log reduction, controls, recovery checks, environmental conditions, and study interpretation.

Standards & guidance

We scope room bioaerosol efficacy studies to the standard or guidance that matches the device, setting, and claim. ISO 17025 is the basis for the laboratory's accredited quality system. ASTM E3273 and ISO 16000-36 provide chamber-study context where applicable; in-duct studies require a separately defined protocol. ASHRAE 241 supplies infectious-aerosol control context. We document AHAM AC-1 adaptations and select EPA OPP claim requirements for the product and intended use.

QA & Regulatory - Accredited

ISO 17025

Testing-laboratory competence, documented methods, calibration traceability, uncertainty, and data reviewView standard ->Bioaerosol & Indoor Air - Aligned

ASHRAE 241

Control of infectious aerosols and equivalent clean airflow context for building and room air-treatment studiesView standard ->Bioaerosol & Indoor Air - Aligned

ASTM E3273

Airborne microorganism reduction context for chamber-based air-treatment efficacy studiesView standard ->EPA & Claims - Aligned

EPA OPP

EPA Office of Pesticide Programs context for applicable antimicrobial claims under FIFRAView standard ->Air Treatment - Aligned

AHAM AC-1

Portable air cleaner chamber-performance context used to structure room device comparisonsView standard ->Bioaerosol & Indoor Air - Aligned

ISO 16000-36

Indoor air test chamber context for airborne microorganism reduction studiesView standard ->

Related services & devices

What We Test

Biological Organisms We Test

Explore biological organisms used in ARE Labs testing, including bacteria, spore-formers, mold, yeast, and bacteriophages. Find a starting point for your study.Read more ->Service

Bioaerosol Reduction Inline

Use when the reduction question is in a duct, tube, or enclosed flow path rather than a room chamber.Read more ->Devices

Air Treatment

Portable, in-duct, UVGI, and hybrid air-cleaning devices that need microbial reduction data under defined airflow.Read more ->Service

Device Challenge Aerosol

Pairs with efficacy studies when the device response or sensor output must be checked against a measured challenge.Read more ->Devices

Medical Devices

Patient-facing and clinical devices where airborne microbial reduction or exposure-control data support design decisions.Read more ->